Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q3 2025 value amounting to $5600.0.

  • Whitehawk Therapeutics' Depreciation and Depletion fell 8800.86% to $5600.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $131900.0, marking a year-over-year decrease of 4039.77%. This contributed to the annual value of $200000.0 for FY2024, which is 0.0% changed from last year.
  • Per Whitehawk Therapeutics' latest filing, its Depreciation and Depletion stood at $5600.0 for Q3 2025, which was down 8800.86% from $15300.0 recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year Depreciation and Depletion high stood at $75000.0 for Q4 2023, and its period low was $5600.0 during Q3 2025.
  • Over the past 4 years, Whitehawk Therapeutics' median Depreciation and Depletion value was $45350.0 (recorded in 2023), while the average stood at $41248.3.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 3157.89% in 2024, then crashed by 8800.86% in 2025.
  • Over the past 4 years, Whitehawk Therapeutics' Depreciation and Depletion (Quarter) stood at $16780.0 in 2021, then skyrocketed by 346.96% to $75000.0 in 2023, then dropped by 28.0% to $54000.0 in 2024, then plummeted by 89.63% to $5600.0 in 2025.
  • Its Depreciation and Depletion stands at $5600.0 for Q3 2025, versus $15300.0 for Q2 2025 and $57000.0 for Q1 2025.